Syros Pharmaceuticals IPO

6/30/2016

IPO

$50,000,000

We currently estimate that we will use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: approximately $25.0 million to fund our proof-of-concept Phase 2 clinical trial of SY-1425 in AML and MDS, including clinical research outsourcing, drug manufacturing, companion diagnostic development and internal personnel costs, with costs to be approximately allocated based on the number of AML and MDS patients enrolled in this trial, respectively; approximately $20.0 million to complete our IND-enabling activities and the Phase 1 portion of our planned Phase 1/2 clinical trial for SY-1365, including clinical research outsourcing, drug manufacturing and internal personnel costs; approximately $40.0 million for new and ongoing research activities, including for our preclinical programs and our platform with a goal of systematically delivering additional INDs; and the remainder for working capital and other general corporate purposes.

Publicly-held

Biopharmaceutical

620 Memorial Dr. 300
Cambridge, MA 02139
USA

Syros Pharmaceuticals (Nasdaq: SYRS) is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities.